XXII - 22nd Century Group, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
2.81
+0.02 (+0.72%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.79
Open2.80
Bid0.00 x 4000
Ask0.00 x 800
Day's Range2.75 - 2.85
52 Week Range1.92 - 4.44
Volume2,642,879
Avg. Volume1,903,987
Market Cap349.494M
Beta2.34
PE Ratio (TTM)N/A
EPS (TTM)-0.10
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.50
Trade prices are not sourced from all markets
  • Business Wire19 days ago

    JAMA Publishes Greatly Anticipated Phase III Study Using 22nd Century’s SPECTRUM® Very Low Nicotine Content Cigarettes

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announced today that the Journal of the American Medical Association (JAMA) published results of a greatly anticipated independent clinical study investigating the effects of an immediate reduction in nicotine content of cigarettes versus a gradual reduction in nicotine content of cigarettes. Dr. Dorothy Hatsukami and other highly respected scientists used exclusively 22nd Century’s SPECTRUM® research cigarettes to conduct this study.

  • Why Are Insiders Pessimistic About 22nd Century Group Inc’s (NYSEMKT:XXII) Stock?
    Simply Wall St.last month

    Why Are Insiders Pessimistic About 22nd Century Group Inc’s (NYSEMKT:XXII) Stock?

    22nd Century Group, Inc., a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabisRead More...

  • Business Wirelast month

    22nd Century Receives Order for 3.6 Million SPECTRUM® U.S. Government Research Cigarettes

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announced today that the National Institute on Drug Abuse (NIDA), the U.S. Food and Drug Administration (FDA), and public health researchers have requested a new, significant quantity of 22nd Century’s proprietary SPECTRUM® research cigarettes. In coordination with NIDA, FDA, and others, RTI International has submitted an order to 22nd Century for 3.6 million SPECTRUM® research cigarettes.

  • Is 22nd Century Group, Inc. a Buy?
    Motley Foollast month

    Is 22nd Century Group, Inc. a Buy?

    The FDA might help this biotech corner the U.S. tobacco market.

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within Cboe Global Markets, Sanderson Farms, National Oilwell Varco, Brighthouse Financial, VeriSign, and 22nd Century Group — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Aug. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cboe ...

  • Associated Press2 months ago

    22nd Century: 2Q Earnings Snapshot

    On a per-share basis, the Williamsville, New York-based company said it had a loss of 5 cents. The plant biotechnology company posted revenue of $6.9 million in the period. In the final minutes of trading ...

  • Business Wire2 months ago

    22nd Century Files 2018 Second Quarter Report

    Company significantly increases spending and strategic initiatives in support of MRTP application and FDA’s ANPRM for reduced nicotine cigarettes. 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, Very Low Nicotine tobacco, and hemp/cannabis research, announced today the Company’s second quarter 2018 financial results. 22nd Century will provide a business update for investors on a conference call to be held Wednesday, August 8, 2018, at 4:00 PM (Eastern Time).

  • Who Are The Top Investors In 22nd Century Group Inc (NYSEMKT:XXII)?
    Simply Wall St.2 months ago

    Who Are The Top Investors In 22nd Century Group Inc (NYSEMKT:XXII)?

    In this analysis, my focus will be on developing a perspective on 22nd Century Group Inc’s (NYSEMKT:XXII) latest ownership structure, a less discussed, but important factor. The impact of aRead More...

  • Business Wire2 months ago

    Washington Examiner Publishes Public Policy Article by 22nd Century’s James Vail and Juan Sanchez Tamburrino, Ph.D.

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announced today that The Washington Examiner published an op-ed article by James Vail, Director of Communications, and Juan Sanchez Tamburrino, Ph.D. Vice President of Research and Development, at 22nd Century. The article calls for the U.S. Congress, tobacco control advocates, and the American people “to ensure that the FDA’s nicotine reduction plan quickly becomes reality.” Dr. Scott Gottlieb, Commissioner of the U.S. Food and Drug Association (FDA), has stated that the FDA’s efforts to lower nicotine in cigarettes will be based on science.

  • Business Wire2 months ago

    Nondaily Smokers Who Switch to 22nd Century’s Very Low Nicotine Content Cigarettes Reduce their Consumption by a Staggering 51%

    In conducting this important clinical trial, study authors Saul Shiffman, Ph.D., Brenda Kurland, Ph.D., Sarah Scholl, MPH, and Jason Mao, B.S. used 22nd Century’s proprietary SPECTRUM® VLNC cigarettes and standard nicotine content cigarettes.

  • Business Wire2 months ago

    22nd Century Announces the Immediate Feasibility of the FDA’s Nicotine Reduction Plan

    22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine tobacco, yesterday responded to the Advance Notice of Proposed Rulemaking (ANPRM) by the U.S. Food and Drug Administration (FDA) to develop a rule that will require all cigarettes sold in the United States to contain only minimally or non-addictive levels of nicotine. When the Company’s response is posted online by the FDA at www.regulations.gov, the corresponding tracking number will be: 1k2-94b8-wdcp. 22nd Century’s complete response to the FDA’s ANPRM is currently available at: www.xxiicentury.com/ANPRM.

  • Is This Former Top-Performing Marijuana Stock Now a Bargain?
    Motley Fool2 months ago

    Is This Former Top-Performing Marijuana Stock Now a Bargain?

    22nd Century Group was a top-performing marijuana stock last year, but things have drastically changed for the company halfway into 2018.

  • Here's Why Marijuana and Tobacco Stock 22nd Century Group Rose 16% in June
    Motley Fool2 months ago

    Here's Why Marijuana and Tobacco Stock 22nd Century Group Rose 16% in June

    ETFs and mutual funds are adding the company. Should you?

  • Business Wire2 months ago

    22nd Century Reports on New Responses to the FDA’s Nicotine Reduction Plan

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine tobacco, today highlights two important submissions to the U.S. Food and Drug Administration (FDA). Altogether, nine separate researchers authored these particular submissions in response to the FDA’s Advance Notice of Proposed Rulemaking (ANPRM) to require that nicotine levels in combustible cigarettes be lowered to minimally or non-addictive levels. 22nd Century’s proprietary VLN™ tobacco cigarettes were used by the FDA in formulating the Agency’s plan to dramatically reduce the nicotine content of cigarettes.

  • ACCESSWIRE3 months ago

    Free Technical Reports on 22nd Century Group and Three Additional Biotech Equities

    Stock Research Monitor: RGNX, RGLS, and ABEO LONDON, UK / ACCESSWIRE / July 5, 2018 / If you want a free Stock Review on XXII sign up now at www.wallstequities.com/registration . For today, WallStEquities.com ...

  • Business Wire3 months ago

    22nd Century Highlights Public Comments to the FDA’s Nicotine Reduction Plan

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine tobacco, today called attention to comments submitted to the U.S. Food and Drug Administration (FDA) in response to the FDA’s Advance Notice of Proposed Rulemaking (ANPRM) to develop a nicotine product standard in cigarettes that will lower nicotine to minimally or non-addictive levels.

  • Business Wire3 months ago

    22nd Century Announces New Non-GMO, Very Low Nicotine Flue-Cured and Burley Tobacco Varieties

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine tobacco, announced today that the Company has exclusively licensed from North Carolina State University (NCSU) several flue-cured and burley tobacco plant lines that grow with Very Low Nicotine levels. The new, non-GMO, Very Low Nicotine tobacco plant lines are immediately commercially viable as they are the result of multiple generations of plantings that have yielded stable, true-breeding crop lines of Very Low Nicotine flue-cured and burley tobacco plants.

  • Business Wire3 months ago

    22nd Century Group Added to Russell 2000, Russell 3000 and Russell Global Indexes

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine tobacco, and hemp/cannabis research, announced today that the Company was added to the Russell 2000, Russell 3000, and Russell Global indexes on June 22, 2018 when Russell FTSE (Russell) reconstituted its U.S. and global equity indexes. Russell added 22nd Century to the Russell Microcap index in 2017.

  • ACCESSWIRE3 months ago

    Today's Research Reports on Stocks to Watch: 22nd Century Group and Palatin Technologies

    NEW YORK, NY / ACCESSWIRE / June 25, 2018 / Both 22 nd Century Group and Palatin Technologies saw their shares jump on Friday despite either company announcing any significant news. RDI Initiates Coverage ...

  • Business Wire3 months ago

    22nd Century Conducts Three Short-Term Studies in Support of the Company’s MRTP Application to the FDA

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine Content tobacco, announced that the Company has initiated three short-term studies investigating the behavioral and biochemical responses to the Company’s proprietary Very Low Nicotine Content tobacco. 22nd Century scientists will submit to the FDA the data collected from these studies as part of the Company’s revised and enhanced Modified Risk Tobacco Product (MRTP) application for “BRAND A” Very Low Nicotine Content cigarettes.

  • Business Wire3 months ago

    22nd Century Group to be Added to Russell 2000, Russell 3000, and Russell Global Indexes

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine tobacco, and hemp/cannabis research, announced today that the Company will be added to the Russell 2000, Russell 3000, and Russell Global Indexes when FTSE Russell (Russell) reconstitutes its U.S. and global equity indexes on June 22, 2018. Russell’s preliminary announcement of its annual reconstitution of these Indexes, which includes 22nd Century Group, was posted on the Russell website on Friday, June 8, 2018, after the U.S. stock market closed.

  • ACCESSWIRE4 months ago

    Free Technical Research on Versartis and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on VSAR sign up now at www.wallstequities.com/registration. This Tuesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Versartis Inc. (NASDAQ: VSAR), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), 22nd Century Group Inc. (NYSE AMER: XXII), and Abeona Therapeutics Inc. (NASDAQ: ABEO).

  • Business Wire4 months ago

    22nd Century to Present to Institutional Investors at the Citi 2018 Small & Mid Cap Conference

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, Very Low Nicotine tobacco, and hemp/cannabis research, today announced that the Company will present at the Citi 2018 Small & Mid Cap Conference at the Lotte New York Palace Hotel, New York, NY on Wednesday, June 6, 2018 at 8:00AM Eastern Time. Henry Sicignano III, President and Chief Executive Officer of 22nd Century Group, will deliver a formal presentation to institutional investors and will discuss the Company’s recent business highlights and updates. Mr. Sicignano will also be available for one-on-one meetings with investors at the conference.

  • Business Wire4 months ago

    Altria, Reynolds, Lorillard, and Philip Morris Ordered to Issue Corrective Statements on Nicotine Addiction; 22nd Century’s Proprietary VLN (TM) Tobacco Called “Minimally or Non-Addictive”

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine tobacco, announced that on May 1, 2018, a federal court ordered Altria, R.J. Reynolds Tobacco, Lorillard, and Philip Morris USA to issue statements to correct marketing that deliberately deceived the public about the addictiveness and health risks of smoking.

  • Benzinga4 months ago

    Cannabis Hedge Fund Managers On The Two Biggest Problems Marijuana Businesses Face

    A few weeks ago, Benzinga had the chance to visit the offices of Poseidon Asset Management, a San Francisco-based cannabis-focused long/short hedge fund with more than $40 million in assets under management. Co-founder and managing partner Emily Paxhia mentioned and her brother and partner Morgan Paxhia have helped turn around multiple companies.